Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer.

Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M, Diamandis EP.

Int J Cancer. 2009 Jul 1;125(1):9-14. doi: 10.1002/ijc.24292.

3.

Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors.

Carbotti G, Orengo AM, Mezzanzanica D, Bagnoli M, Brizzolara A, Emionite L, Puppo A, Centurioni MG, Bruzzone M, Marroni P, Rossello A, Canevari S, Ferrini S, Fabbi M.

Int J Cancer. 2013 Jun 1;132(11):2597-605. doi: 10.1002/ijc.27948. Epub 2012 Dec 13.

4.

HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.

Zeiwar MM, Zaki SM, Mohammad LA, Zidan AA, El Nagar MR.

Egypt J Immunol. 2007;14(2):29-41.

PMID:
20306655
5.

Activated Leukocyte Cell Adhesion Molecule (ALCAM) in Saudi Breast Cancer Patients as Prognostic and Predictive Indicator.

Al-Shehri FS, Abd El Azeem EM.

Breast Cancer (Auckl). 2015 Sep 23;9:81-6. doi: 10.4137/BCBCR.S25563. eCollection 2015.

6.

Serum microRNA-155 as a potential biomarker to track disease in breast cancer.

Sun Y, Wang M, Lin G, Sun S, Li X, Qi J, Li J.

PLoS One. 2012;7(10):e47003. doi: 10.1371/journal.pone.0047003. Epub 2012 Oct 10.

7.

Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.

Shao Y, Sun X, He Y, Liu C, Liu H.

PLoS One. 2015 Jul 24;10(7):e0133830. doi: 10.1371/journal.pone.0133830. eCollection 2015.

8.

Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer.

Wang G, Qin Y, Zhang J, Zhao J, Liang Y, Zhang Z, Qin M, Sun Y.

Int J Mol Sci. 2014 May 28;15(6):9546-65. doi: 10.3390/ijms15069546.

9.

Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients.

Ihnen M, Kress K, Kersten JF, Kilic E, Choschzick M, Zander H, Müller V, Mahner S, Jänicke F, Woelber L, Milde-Langosch K.

BMC Cancer. 2012 Apr 4;12:140. doi: 10.1186/1471-2407-12-140.

10.

Detection of activated leukocyte cell adhesion molecule in the serum of breast cancer patients and implications for prognosis.

Witzel I, Schröder C, Müller V, Zander H, Tachezy M, Ihnen M, Jänicke F, Milde-Langosch K.

Oncology. 2012;82(6):305-12. doi: 10.1159/000337222. Epub 2012 May 3.

PMID:
22555284
12.

Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.

El-Attar NI, Gaefar HA.

Egypt J Immunol. 2007;14(2):111-21.

PMID:
20306663
13.

Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen.

Daly L, Ferguson J, Cram GP Jr, Hars V, George SL, McCarty KS Jr, Bast RC Jr.

J Clin Oncol. 1992 Jul;10(7):1057-65.

PMID:
1607912
14.

Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).

Giovanella L, Ceriani L, Giardina G, Bardelli D, Tanzi F, Garancini S.

Clin Chem Lab Med. 2002 Mar;40(3):298-303.

PMID:
12005221
15.

ALCAM (CD166) expression and serum levels in pancreatic cancer.

Tachezy M, Zander H, Marx AH, Stahl PR, Gebauer F, Izbicki JR, Bockhorn M.

PLoS One. 2012;7(6):e39018. doi: 10.1371/journal.pone.0039018. Epub 2012 Jun 20.

16.
17.

Circulating levels and clinical implications of epithelial membrane antigen and cytokeratin-1 in women with breast cancer: can their ratio improve the results?

Attallah AM, El-Far M, Omran MM, Abdallah SO, El-Desouky MA, El-Dosoky I, Abdelrazek MA, Attallah AA, Elweresh MA, Abdel Hameed GE, Shawki HA, Salama KS, El-Waseef AM.

Tumour Biol. 2014 Nov;35(11):10737-45. doi: 10.1007/s13277-014-2375-1. Epub 2014 Jul 30.

PMID:
25073515
18.

The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.

Frenette PS, Thirlwell MP, Trudeau M, Thomson DM, Joseph L, Shuster JS.

Tumour Biol. 1994;15(5):247-54.

PMID:
7991985
19.

Assay of serum CEACAM1 as a potential biomarker for breast cancer.

Yang C, He P, Liu Y, He Y, Yang C, Du Y, Zhou M, Wang W, Zhang G, Wu M, Gao F.

Clin Chim Acta. 2015 Oct 23;450:277-81. doi: 10.1016/j.cca.2015.09.005. Epub 2015 Sep 4.

PMID:
26343926
20.

Vitronectin: a promising breast cancer serum biomarker for early diagnosis of breast cancer in patients.

Hao W, Zhang X, Xiu B, Yang X, Hu S, Liu Z, Duan C, Jin S, Ying X, Zhao Y, Han X, Hao X, Fan Y, Johnson H, Meng D, Persson JL, Zhang H, Feng X, Huang Y.

Tumour Biol. 2016 Jul;37(7):8909-16. doi: 10.1007/s13277-015-4750-y. Epub 2016 Jan 11.

PMID:
26753956

Supplemental Content

Support Center